WeVote
Log In

Bill

WeVote Research Nonpartisan
Bill Summary · SB 227

Legislative bill overview

SB 227 would establish a cap on out-of-pocket costs for prescription insulin drugs in Ohio, limiting the amount patients must pay through copayments, coinsurance, or deductibles. The bill aims to make insulin more affordable by preventing excessive cost-sharing burdens on diabetic patients who require regular insulin treatment.

Why is this important

Insulin is a life-sustaining medication for millions of Americans with diabetes, yet many patients face significant financial barriers to accessing it due to high out-of-pocket costs. Without affordability protections, patients may ration doses or skip treatments, leading to serious health complications, hospitalizations, and reduced quality of life. This bill directly addresses a documented public health and economic burden affecting working families and vulnerable populations.

Potential points of contention

  • Insurance market impact: Critics may argue that cost-sharing caps could increase premiums for all insured Ohioans or reduce insurer participation in the state market, potentially offsetting savings for insulin users
  • Scope and definition: Questions remain about which insulin products are covered, whether the cap applies to all health plans equally, and how it coordinates with federal insulin pricing policies already in effect
  • Funding mechanism: The bill's approach to ensuring pharmaceutical companies and insurers absorb costs rather than passing them to other patients or increasing overall healthcare spending is unclear

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.